{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:49:00Z","timestamp":1794948540377,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL141966"],"award-info":[{"award-number":["R01HL141966"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL143520"],"award-info":[{"award-number":["R01HL143520"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K08AR079587"],"award-info":[{"award-number":["K08AR079587"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of the mechanisms of arthritis-irAE is critical to overcome this challenge, but the pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and\/or synovial fluid samples from 20 patients with arthritis-irAE, and unmask a prominent Th1-CD8<jats:sup>+<\/jats:sup> T cell axis in both blood and inflamed joints. CX3CR1<jats:sup>hi<\/jats:sup> CD8<jats:sup>+<\/jats:sup> T cells in blood and CXCR3<jats:sup>hi<\/jats:sup> CD8<jats:sup>+<\/jats:sup> T cells in synovial fluid, the most clonally expanded T cells, significantly share TCR repertoires. The migration of blood CX3CR1<jats:sup>hi<\/jats:sup> CD8<jats:sup>+<\/jats:sup> T cells into joints is possibly mediated by CXCL9\/10\/11\/16 expressed by myeloid cells. Furthermore, arthritis after combined CTLA-4 and PD-1 inhibitor therapy preferentially has enhanced Th17 and transient Th1\/Th17 cell signatures. Our data provide insights into the mechanisms, predictive biomarkers, and therapeutic targets for arthritis-irAE.<\/jats:p>","DOI":"10.1038\/s41467-022-29539-3","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T10:03:01Z","timestamp":1649757781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-1840","authenticated-orcid":false,"given":"Sang T.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshuo","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Misoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H.","family":"Tayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Buni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulekha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-0621","authenticated-orcid":false,"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-3094","authenticated-orcid":false,"given":"Don L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-5407","authenticated-orcid":false,"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica E.","family":"Loghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1899-3501","authenticated-orcid":false,"given":"Janet","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C. Glitza","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-5118","authenticated-orcid":false,"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-0266","authenticated-orcid":false,"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-1121","authenticated-orcid":false,"given":"Roza","family":"Nurieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"29539_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/art.40043","volume":"69","author":"ME Suarez-Almazor","year":"2017","unstructured":"Suarez-Almazor, M. E., Kim, S. T., Abdel-Wahab, N. & Diab, A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 69, 687\u2013699 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"29539_CR2","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"29539_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese, L. H., Calabrese, C. & Cappelli, L. C. Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569\u2013579 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"29539_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"29539_CR5","doi-asserted-by":"crossref","unstructured":"Subedi, A., Strauss, J. & Gupta, S. Erosive deforming inflammatory arthritis in a patient with cervical adenocarcinoma. JAMA Oncol. 5,1628\u20131629 (2019).","DOI":"10.1001\/jamaoncol.2019.3140"},{"key":"29539_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"29539_CR7","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706\u20133714 (2018).","journal-title":"Cancer"},{"key":"29539_CR8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott, S. C. & Pennell, N. A. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J. Thorac. Oncol. 13, 1771\u20131775 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"29539_CR9","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275\u20134280 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"29539_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman, R. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29, 1039\u20131049 (1986).","journal-title":"Arthritis Rheum."},{"key":"29539_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","volume":"31","author":"X Pundole","year":"2019","unstructured":"Pundole, X., Abdel-Wahab, N. & Suarez-Almazor, M. E. Arthritis risk with immune checkpoint inhibitor therapy for cancer. Curr. Opin. Rheumatol. 31, 293\u2013299 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"29539_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","volume":"48","author":"LC Cappelli","year":"2018","unstructured":"Cappelli, L. C. et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 48, 553\u2013557 (2018).","journal-title":"Semin Arthritis Rheum."},{"key":"29539_CR13","doi-asserted-by":"publisher","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","volume":"4","author":"J Leipe","year":"2018","unstructured":"Leipe, J. et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4, e000714 (2018).","journal-title":"RMD Open"},{"key":"29539_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","volume":"67","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya, K. et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol. Immunother. 67, 175\u2013182 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"29539_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson, J. et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64, 640\u2013647 (2012).","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"29539_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0597-x","volume":"7","author":"ST Kim","year":"2019","unstructured":"Kim, S. T. et al. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J. Immunother. Cancer 7, 126 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"29539_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"29539_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","volume":"8","author":"JE Craft","year":"2012","unstructured":"Craft, J. E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 8, 337\u2013347 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"29539_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"29539_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.it.2012.11.002","volume":"34","author":"E Cretney","year":"2013","unstructured":"Cretney, E., Kallies, A. & Nutt, S. L. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 34, 74\u201380 (2013).","journal-title":"Trends Immunol."},{"key":"29539_CR21","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1172\/JCI130426","volume":"130","author":"G Alvisi","year":"2020","unstructured":"Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130, 3137\u20133150 (2020).","journal-title":"J. Clin. Invest."},{"key":"29539_CR22","doi-asserted-by":"crossref","unstructured":"Lucca, L. E. et al. TIGIT signaling restores suppressor function of Th1 Tregs. JCI insight 4, e124427 (2019).","DOI":"10.1172\/jci.insight.124427"},{"key":"29539_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","volume":"49","author":"D Bauche","year":"2018","unstructured":"Bauche, D. et al. LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Immunity 49, 342\u2013352 e345 (2018).","journal-title":"Immunity"},{"key":"29539_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.celrep.2017.10.090","volume":"21","author":"X Wei","year":"2017","unstructured":"Wei, X. et al. Reciprocal Expression of IL-35 and IL-10 defines two distinct effector treg subsets that are required for maintenance of immune tolerance. Cell Rep. 21, 1853\u20131869 (2017).","journal-title":"Cell Rep."},{"key":"29539_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07735-4","volume":"9","author":"SI Koizumi","year":"2018","unstructured":"Koizumi, S. I. et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat. Commun. 9, 5344 (2018).","journal-title":"Nat. Commun."},{"key":"29539_CR26","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346\u20131358 (2020).","journal-title":"Nat. Immunol."},{"key":"29539_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745\u2013763 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"29539_CR28","doi-asserted-by":"publisher","first-page":"17872","DOI":"10.1073\/pnas.1010201107","volume":"107","author":"LM Wakim","year":"2010","unstructured":"Wakim, L. M., Woodward-Davis, A. & Bevan, M. J. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl Acad. Sci. 107, 17872\u201317879 (2010).","journal-title":"Proc. Natl Acad. Sci."},{"key":"29539_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4049\/jimmunol.176.1.537","volume":"176","author":"KH Ely","year":"2006","unstructured":"Ely, K. H., Cookenham, T., Roberts, A. D. & Woodland, D. L. Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176, 537\u2013543 (2006).","journal-title":"J. Immunol."},{"key":"29539_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature10339","volume":"477","author":"T Gebhardt","year":"2011","unstructured":"Gebhardt, T. et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 477, 216\u2013219 (2011).","journal-title":"Nature"},{"key":"29539_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S243636","volume":"9","author":"NM Elemam","year":"2020","unstructured":"Elemam, N. M., Hannawi, S. & Maghazachi, A. A. Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther. 9, 43\u201356 (2020).","journal-title":"Immunotargets Ther."},{"key":"29539_CR32","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4049\/jimmunol.1701217","volume":"201","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Human extrafollicular CD4(+) Th cells help memory B cells produce Igs. J. Immunol. 201, 1359\u20131372 (2018).","journal-title":"J. Immunol."},{"key":"29539_CR33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133 e1117 (2017).","journal-title":"Cell"},{"key":"29539_CR34","doi-asserted-by":"crossref","unstructured":"Braaten, T. J. et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann. Rheum. Dis. 79, 332\u2013338 (2019).","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"29539_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745\u2013756 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"29539_CR36","doi-asserted-by":"crossref","unstructured":"Kishimoto, T., Kang, S. & Tanaka, T. IL-6: A New Era for the treatment of autoimmune inflammatory diseases. in Innovative Medicine: Basic Research and Development (eds. Nakao, K., Minato, N. & Uemoto, S.) 131\u2013147 (Tokyo, 2015).","DOI":"10.1007\/978-4-431-55651-0_11"},{"key":"29539_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1196\/annals.1443.021","volume":"1143","author":"GJ Martinez","year":"2008","unstructured":"Martinez, G. J., Nurieva, R. I., Yang, X. O. & Dong, C. Regulation and function of proinflammatory TH17 cells. Ann. N. Y Acad. Sci. 1143, 188\u2013211 (2008).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"29539_CR38","doi-asserted-by":"crossref","unstructured":"Naing, A. et al. Strategies for improving the management of immune-related adverse events. J. Immunother. Cancer 8, e001754 (2020).","DOI":"10.1136\/jitc-2020-001754"},{"key":"29539_CR39","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3389\/fimmu.2018.01508","volume":"9","author":"M Tang","year":"2018","unstructured":"Tang, M., Tian, L., Luo, G. & Yu, X. Interferon-gamma-mediated osteoimmunology. Front. Immunol. 9, 1508 (2018).","journal-title":"Front. Immunol."},{"key":"29539_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2019.00353","volume":"10","author":"K Chemin","year":"2019","unstructured":"Chemin, K., Gerstner, C. & Malmstrom, V. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front. Immunol. 10, 353 (2019).","journal-title":"Front. Immunol."},{"key":"29539_CR41","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/art.22453","volume":"56","author":"CQ Chu","year":"2007","unstructured":"Chu, C. Q., Swart, D., Alcorn, D., Tocker, J. & Elkon, K. B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 56, 1145\u20131151 (2007).","journal-title":"Arthritis Rheum."},{"key":"29539_CR42","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/eji.1830250508","volume":"25","author":"MC Boissier","year":"1995","unstructured":"Boissier, M. C. et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur. J. Immunol. 25, 1184\u20131190 (1995).","journal-title":"Eur. J. Immunol."},{"key":"29539_CR43","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/ar2838","volume":"11","author":"S Sarkar","year":"2009","unstructured":"Sarkar, S. et al. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther. 11, R158 (2009).","journal-title":"Arthritis Res Ther."},{"key":"29539_CR44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"29539_CR45","doi-asserted-by":"publisher","first-page":"154960","DOI":"10.1016\/j.cyto.2019.154960","volume":"127","author":"EJ Lee","year":"2020","unstructured":"Lee, E. J. et al. Bulk and single cell transcriptomic data indicate that a dichotomy between inflammatory pathways in peripheral blood and arthritic joints complicates biomarker discovery. Cytokine 127, 154960 (2020).","journal-title":"Cytokine"},{"key":"29539_CR46","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1002\/art.20499","volume":"50","author":"JM van Amelsfort","year":"2004","unstructured":"van Amelsfort, J. M., Jacobs, K. M., Bijlsma, J. W., Lafeber, F. P. & Taams, L. S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50, 2775\u20132785 (2004).","journal-title":"Arthritis Rheum."},{"key":"29539_CR47","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3389\/fimmu.2019.02158","volume":"10","author":"M Di Giovangiulio","year":"2019","unstructured":"Di Giovangiulio, M. et al. Tbet expression in regulatory T cells is required to initiate Th1-mediated colitis. Front. Immunol. 10, 2158 (2019).","journal-title":"Front. Immunol."},{"key":"29539_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.celrep.2017.09.021","volume":"21","author":"B-S Kim","year":"2017","unstructured":"Kim, B.-S. et al. Generation of ROR\u03b3t+ antigen-specific T regulatory 17 cells from Foxp3+ precursors in autoimmunity. Cell Rep. 21, 195\u2013207 (2017).","journal-title":"Cell Rep."},{"key":"29539_CR49","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.172.10.6435","volume":"172","author":"IM de Kleer","year":"2004","unstructured":"de Kleer, I. M. et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172, 6435\u20136443 (2004).","journal-title":"J. Immunol."},{"key":"29539_CR50","doi-asserted-by":"publisher","first-page":"1722023","DOI":"10.1080\/2162402X.2020.1722023","volume":"9","author":"KH Kim","year":"2020","unstructured":"Kim, K. H. et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 9, 1722023 (2020).","journal-title":"Oncoimmunology"},{"key":"29539_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin, J. J. et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).","journal-title":"Nat. Commun."},{"key":"29539_CR52","doi-asserted-by":"crossref","unstructured":"Yan, Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI insight 3, e97828 (2018).","DOI":"10.1172\/jci.insight.97828"},{"key":"29539_CR53","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"29539_CR54","doi-asserted-by":"publisher","first-page":"e1386362","DOI":"10.1080\/2162402X.2017.1386362","volume":"7","author":"H Laubli","year":"2018","unstructured":"Laubli, H. et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology 7, e1386362 (2018).","journal-title":"Oncoimmunology"},{"key":"29539_CR55","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1002\/art.10622","volume":"46","author":"T Nanki","year":"2002","unstructured":"Nanki, T. et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2878\u20132883 (2002).","journal-title":"Arthritis Rheum."},{"key":"29539_CR56","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/art.34330","volume":"64","author":"M Yellin","year":"2012","unstructured":"Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1730\u20131739 (2012).","journal-title":"Arthritis Rheum."},{"key":"29539_CR57","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1002\/art.21301","volume":"52","author":"T Nanki","year":"2005","unstructured":"Nanki, T. et al. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 52, 3004\u20133014 (2005).","journal-title":"Arthritis Rheum."},{"key":"29539_CR58","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/art.21662","volume":"54","author":"JH Ruth","year":"2006","unstructured":"Ruth, J. H. et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 54, 765\u2013778 (2006).","journal-title":"Arthritis Rheum."},{"key":"29539_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207\u2013215 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"29539_CR60","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1053\/j.gastro.2019.01.247","volume":"156","author":"JC Mossanen","year":"2019","unstructured":"Mossanen, J. C. et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence. Gastroenterology 156, 1877\u20131889 e1874 (2019).","journal-title":"Gastroenterology"},{"key":"29539_CR61","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.4049\/jimmunol.181.6.4089","volume":"181","author":"L McKinley","year":"2008","unstructured":"McKinley, L. et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181, 4089\u20134097 (2008).","journal-title":"J. Immunol."},{"key":"29539_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1084\/jem.20130301","volume":"211","author":"R Ramesh","year":"2014","unstructured":"Ramesh, R. et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89\u2013104 (2014).","journal-title":"J. Exp. Med."},{"key":"29539_CR63","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0903369","volume":"185","author":"H Ying","year":"2010","unstructured":"Ying, H. et al. Cutting edge: CTLA-4\u2013B7 interaction suppresses Th17 cell differentiation. J. Immunol. 185, 1375\u20131378 (2010).","journal-title":"J. Immunol."},{"key":"29539_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw, E. et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).","journal-title":"J. Transl. Med."},{"key":"29539_CR65","doi-asserted-by":"crossref","unstructured":"Kotake, S., Yago, T., Kobashigawa, T. & Nanke, Y. The Plasticity of Th17 cells in the pathogenesis of rheumatoid arthritis. J. Clin. Med. 6, 67 (2017).","DOI":"10.3390\/jcm6070067"},{"key":"29539_CR66","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fimmu.2019.00450","volume":"10","author":"L Maggi","year":"2019","unstructured":"Maggi, L. et al. Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis. Front. Immunol. 10, 450 (2019).","journal-title":"Front. Immunol."},{"key":"29539_CR67","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.4049\/jimmunol.1600737","volume":"198","author":"SA Basdeo","year":"2017","unstructured":"Basdeo, S. A. et al. Ex-Th17 (Nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells. J. Immunol. 198, 2249\u20132259 (2017).","journal-title":"J. Immunol."},{"key":"29539_CR68","doi-asserted-by":"crossref","unstructured":"Murray-Brown, W. et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J. Immunother. Cancer 8, e000281 (2020).","DOI":"10.1136\/jitc-2019-000281"},{"key":"29539_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18513-6","volume":"11","author":"F Penkava","year":"2020","unstructured":"Penkava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. 11, 4767 (2020).","journal-title":"Nat. Commun."},{"key":"29539_CR70","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671 e622 (2020).","journal-title":"Cell"},{"key":"29539_CR71","doi-asserted-by":"crossref","unstructured":"Osa, A. et al. Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients. JCI insight 3, e59125 (2018).","DOI":"10.1172\/jci.insight.59125"},{"key":"29539_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-0888-1","volume":"17","author":"T Ilicic","year":"2016","unstructured":"Ilicic, T. et al. Classification of low quality cells from single-cell RNA-seq data. Genome Biol. 17, 1\u201315 (2016).","journal-title":"Genome Biol."},{"key":"29539_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).","journal-title":"Nat. Commun."},{"key":"29539_CR74","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-020-1125-8","volume":"27","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat. Med. 27, 141\u2013151 (2021).","journal-title":"Nat. Med."},{"key":"29539_CR75","doi-asserted-by":"crossref","unstructured":"Sinjab, A. et al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. 11, 2506\u20132523 (2021).","DOI":"10.1158\/2159-8290.CD-20-1285"},{"key":"29539_CR76","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291 e289 (2019).","journal-title":"Cell Syst."},{"key":"29539_CR77","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"29539_CR78","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u20131902 e1821 (2019).","journal-title":"Cell"},{"key":"29539_CR79","doi-asserted-by":"crossref","unstructured":"McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426 (2018).","DOI":"10.21105\/joss.00861"},{"key":"29539_CR80","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277\u20131289 (2018).","journal-title":"Nat. Med."},{"key":"29539_CR81","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 e1020 (2018).","journal-title":"Cell"},{"key":"29539_CR82","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459 e429 (2020).","journal-title":"Cell"},{"key":"29539_CR83","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. iTALK: an R package to characterize and illustrate intercellular communication. BioRxiv, 507871 (2019).","DOI":"10.1101\/507871"},{"key":"29539_CR84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/eji.201141651","volume":"42","author":"AN McMurchy","year":"2012","unstructured":"McMurchy, A. N. & Levings, M. K. Suppression assays with human T regulatory cells: a technical guide. Eur. J. Immunol. 42, 27\u201334 (2012).","journal-title":"Eur. J. Immunol."}],"updated-by":[{"DOI":"10.1038\/s41467-024-49733-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29539-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:02:48Z","timestamp":1720162968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29539"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29539-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-024-49733-9","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-49733-9","URL":"https:\/\/doi.org\/10.1038\/s41467-024-49733-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.-A. has served as a consultant for Gilead, Avenue Therapeutics, ChemoCentryx, Pfizer, Eli Lilly and Bristol Myers Squibb. N.A.-W. has received honoraria for serving on a scientific advisory board for ChemoCentryx and served as a consultant for ChemoCentryx. S.S.N. has received personal fees from Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Sellas Life Sciences, Cell Medica\/Kuur\/Athenex, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics, Bluebird Bio, and Sana Biotechnology; research support from Kite, a Gilead Company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, Acerta, and Adicet Bio; royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy. M.T.C. has received honoraria for serve on a Scientific Advisory Board for Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, served as a consultant for ApricityHealth, Exelixis, Pfizer, non-branded educational programs supported by Bristol Myers Squibb, Exelixis, Merck, Pfizer, Roche, and research funding for clinical trials from ApricityHealth, AstraZeneca, EMD Serono\/Pfizer, Exelixis, and Janssen. D.L.G. declares advisory board work for Janssen, AstraZeneca, GlaxoSmithKline and Sanofi. D.L.G. receives research grant funding from AstraZeneca, Janssen, Astellas, Ribon Therapeutics, NGM Therapeutics and Takeda. M.A. declares advisory board work for GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca. M.A. has received speaker fees from AstraZeneca, and Nektar Therapeutics. M.A. received research funding from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, and Shattuck Lab. S.N.W. received research grants to the institution from AstraZeneca, Clovis Oncology, GSK\/Tesaro, Roche\/Genentech, Novartis, Cotinga Pharmaceuticals, Bayer, Bio-Path, and ArQule, and received consulting fees from AstraZeneca, Clovis Oncology, GSK\/Tesaro, Roche\/Genentech, Novartis, Merck, Pfizer, Eisai, Zentalis, Circulogene, and Agenus. A.N. received research grants to the institution from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor\/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol- Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG. M.A.D. has been a consultant to Roche\/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothyreon. T.C. has received speakers\u2019 fees from the Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape Oncology and PeerView Institute for Medical Education; reports consulting\/advisory role fees from MedImmune, AstraZeneca, Bristol Myers Squibb, Merck & Co., Genentech, Arrowhead Pharmaceuticals and EMD Serono; reports institutional clinical research funding from Boehringer Ingelheim, MedImmune, AstraZeneca, EMD Serono, and Bristol Myers Squibb. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1970"}}